Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating Costs and Expenses:        
General and administrative $ 1,197,000 $ 1,098,000 $ 3,876,000 $ 3,297,000
Research and development 914,000 4,144,000 4,152,000 9,156,000
Total Operating Costs and Expenses 2,111,000 5,242,000 8,028,000 12,453,000
Loss from Operations (2,111,000) (5,242,000) (8,028,000) (12,453,000)
Other Income :        
Interest income 0 92,000 44,000 217,000
Total Other Income 0 92,000 44,000 217,000
Net Loss (2,111,000) (5,150,000) (7,984,000) (12,236,000)
Net Loss Attributable to Non-controlling Interest (8,000) (30,000) (50,000) (73,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (2,103,000) (5,120,000) (7,934,000) (12,163,000)
Preferred Stock Dividends, Income Statement Impact       (185,000)
Net Loss Attributable to Common Stockholders $ (2,686,000) $ (5,253,000) $ (9,438,000) $ (12,934,000)
Net Loss Per Share - Basic and Dilutive $ (0.14) $ (0.31) $ (0.52) $ (0.79)
Weighted average number of shares outstanding during the period - Basic and Dilutive 19,398,339 16,805,257 18,302,585 16,313,326
Series A Preferred Stock [Member]        
Other Income :        
Preferred Stock Dividends, Income Statement Impact $ (64,000) $ (63,000) $ (189,000) $ (185,000)
Series B Preferred Stock [Member]        
Other Income :        
Net Loss Attributable to Non-controlling Interest 0 0    
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0    
Preferred Stock Dividends, Income Statement Impact $ (519,000) $ (70,000) $ (1,315,000) $ (585,000)